Cell-Free DNA BCT

FDA 510(k) K231776 · Streck, Inc.

Substantially Equivalent

510(k) numberK231776

Submission

Device name
Cell-Free DNA BCT
Applicant
Streck, Inc.
La Vista, NE, US
Received
June 16, 2023
Decision date
July 26, 2024
Decision
Substantially Equivalent (SESE)
Type
Traditional 510(k)
Summary
510(k) statement available from FDA

Official FDA 510(k) record

Device classification

Product code
QMA – Blood Collection Device For Cell-Free Nucleic Acid
Device class
Class II (moderate risk)
Regulation
21 CFR 862.1676
Specialty
Clinical Chemistry

A blood collection device for cell-free nucleic acids is a device intended for medical purposes to collect, store, transport, and handle blood specimens and to stabilize and isolate cell-free nucleic acid components prior to further testing.

More from Streck, Inc.

510(k)DeviceDecision
K260041MDx-Chex for BCPPMN · Traditional 03/27/2026SE
K254166MDx-Chex for BCNPMN · Traditional 03/23/2026SE
K254167MDx-Chex for BCYPMN · Traditional 03/17/2026SE
K231223MDx-Chex for BC-GNPMN · Traditional 07/27/2023SE
K231221MDx-Chex for BC-GPPMN · Traditional 07/27/2023SE
K212576MDx-Chex for BCID2PMN · Traditional 01/19/2022SE
K170091UA-Cellular CompleteJJW · Traditional 02/09/2017SE
K160590XN CheckJPK · Traditional 12/22/2016SE
K160588XN Check BFJPK · Traditional 12/22/2016SE
K160586Xn-L CheckJPK · Traditional 12/22/2016SE

Questions and answers

When was Cell-Free DNA BCT cleared by the FDA?

Cell-Free DNA BCT (K231776) received a 510(k) decision of Substantially Equivalent on July 26, 2024, 406 days after the submission was received.

What is the product code of K231776?

The FDA product code is QMA – Blood Collection Device For Cell-Free Nucleic Acid, a Class II (moderate risk) device regulated under 21 CFR 862.1676.